首站-论文投稿智能助手
典型文献
Potential application of proteolysis targeting chimera(PROTAC)modification technology in natural products for their targeted protein degradation
文献摘要:
There are numerous evaluations of natural products,of which majority are food bioactives,performed up to date for their various health beneficial activities via targeting specific proteins.However,the direct identification of a targeted protein remains unexplored for natural occurring compounds.Proteolysis targeting chimera(PROTAC)is a type of bifunctional chimeric molecules that can directly degrade the binding proteins targeted by bioactive molecules in an ubiquitin-proteasome pathway.As the agents in protein degradation dependent on ubiquitin ligase,the bifunctional molecule connects the target protein ligand and E3 ligase ligand together via an appropriate linker.It is highly selective and efficient to induce the ubiquitin-mediated degradation of targeted binding proteins.Therefore,it has been demonstrated that the PROTAC technology has broad application in the modulation of the target protein level.In this review,we outlined the advances in PROTAC combined molecule compounds,summarized its quantitative structure-activity relationship,and finally reviewed the methods applied in identifying the target proteins of natural products.We hope it will provide an insightful application of PROTAC techniques in the target protein identification of natural products including food bioactive molecules.
文献关键词:
作者姓名:
Guliang Yang;Haiyan Zhong;Xinxin Xia;Zhiwen Qi;Chengzhang Wang;Shiming Li
作者机构:
National Engineering Laboratory for Rice and By-products Processing,Food Science and Engineering College,Central South University of Forestry and Technology,Changsha 410004,China;Institute of Chemical Industry of Forest Products,CAF,Nanjing 210042,China;Hubei Key Laboratory of Economic Forest Germplasm Improvement and Resources Comprehensive Utilization,Huanggang Normal University,Huanggang 438000,China
引用格式:
[1]Guliang Yang;Haiyan Zhong;Xinxin Xia;Zhiwen Qi;Chengzhang Wang;Shiming Li-.Potential application of proteolysis targeting chimera(PROTAC)modification technology in natural products for their targeted protein degradation)[J].食品科学与人类健康(英文),2022(02):199-207
A类:
bioactives,Proteolysis
B类:
Potential,application,proteolysis,targeting,chimera,PROTAC,modification,technology,natural,products,their,targeted,degradation,are,numerous,evaluations,which,majority,food,performed,up,date,various,health,beneficial,activities,via,specific,proteins,However,identification,remains,unexplored,occurring,compounds,type,bifunctional,chimeric,molecules,that,can,directly,degrade,binding,by,ubiquitin,proteasome,pathway,agents,dependent,ligase,connects,ligand,E3,together,appropriate,linker,It,highly,selective,efficient,induce,mediated,Therefore,has,been,demonstrated,broad,modulation,level,In,this,outlined,advances,combined,summarized,its,quantitative,structure,activity,relationship,finally,reviewed,methods,applied,identifying,We,hope,will,provide,insightful,techniques,including
AB值:
0.519814
相似文献
Deubiquitinase ubiquitin-specific protease 3 (USP3) inhibits HIV-1 replication via promoting APOBEC3G (A3G) expression in both enzyme activity-dependent and -independent manners
Zhao Simin;Zheng Baisong;Wang Liuli;Cui Wenzhe;Jiang Chunlai;Li Zhuo;Gao Wenying;Zhang Wenyan-Center for Pathogen Biology and Infectious Diseases, Institute of Virology and AIDS Research, Key Laboratory of Organ Regeneration and Transplantation of The Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin 130021, China;College of Life Science of Jilin University, Changchun, Jilin 130012, China;Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130012, China;Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, Jilin 130041, China;Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, China
Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy
Xin Sun;Yuhan Shu;Guiqin Ye;Caixia Wu;Mengting Xu;Ruilan Gao;Dongsheng Huang;Jianbin Zhang-Department of Oncology,Cancer Center of Zhejiang Provincial People's Hospital,Affiliated People's Hospital,Hangzhou Medical College,Hangzhou 310014,China;College of Biomedical Engineering&Instrument Science,Zhejiang University,Hangzhou 310028,China;Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province,Hangzhou Medical College,Hangzhou 310014,China;Clinical Research Institute,Zhejiang Provincial People,s Hospital,Affiliated People,s Hospital,Hangzhou Medical College,Hangzhou 310014,China;Department of Hematology,the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,China
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang;Sui Fang;Yan Wu;Xi Cheng;Lei-ke Zhang;Xu-rui Shen;Shuang-qu Li;Jian-rong Xu;Wei-juan Shang;Zhao-bing Gao;Bing-qing Xia-CAS Key Laboratory of Receptor Research,Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Pharmacology and Chemical Biology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Zhongshan Institute of Drug Discovery,Institution for Drug Discovery Innovation,Chinese Academy of Science,Zhongshan 528400,China
Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein
Lin Wang;Yan Wu;Sheng Yao;Huan Ge;Ya Zhu;Kun Chen;Wen-zhang Chen;Yi Zhang;Wei Zhu;Hong-yang Wang;Yu Guo;Pei-xiang Ma;Peng-xuan Ren;Xiang-lei Zhang;Hui-qiong Li;Mohammad A.Ali;Wen-qing Xu;Hua-liang Jiang;Lei-ke Zhang;Li-li Zhu;Yang Ye;Wei-juan Shang;Fang Bai-Shanghai Institute for Advanced Immunochemical Studies,ShanghaiTech University,Shanghai 201210,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430064,China;Department of Natural Products Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;State Key Laboratory of Bioreactor Engineering,Shanghai Key Laboratory of New Drug Design,School of Pharmacy,East China University of Science and Technology,Shanghai 200237,China;CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology,Nankai University,Tianjin 300071,China;Department of Botany and Microbiology,College of Science,King Saud University,Riyadh,Saudi Arabia
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity
Chuan-jing Cheng;Kai-xin Liu;Man Zhang;Fu-kui Shen;Li-li Ye;Wen-bo Wu;Xiao-tao Hou;Er-wei Hao;Yuan-yuan Hou;Gang Bai-State Key Laboratory of Medicinal Chemical Biology,College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research,Nankai University,Tianjin 300353,China;Collaborative Innovation Center of Research on Functional Ingredients from Agricultural Residues,Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica,Guangxi University of Chinese medicine,Nanning 530200,China;China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research,Guangxi University of Chinese Medicine,Nanning 530200,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin
Na Hui Kim;Minji Kwon;Jiwoo Jung;Hyo Byeong Chae;Jiwoo Lee;Yeo-Jun Yoon;In Seok Moon;Ho K.Lee;Wan Namkung;Konstantina M.Stankovic;Se A.Lee;Jong Dae Lee;Sin-Aye Park-Department of ICT Environmental Health System,Graduate School,Soonchunhyang University,Asan-si 31538,Republic of Korea;Department of Biomedical Laboratory Science,College of Medical Sciences,Soonchunhyang University,Asan-si 31538,Republic of Korea;Department of Otorhinolaryngology,Yonsei University,College of Medicine,Seoul 03722,Republic of Korea;Colllege of Pharmacy and Yonsei Institute of Pharmaceutical Sciences,Yonsei University,Yeonsu-gu,Incheon 21983,Republic of Korea;Department of Otolaryngology-Head and Neck Surgery,Stanford University School of Medicine,Stanford,CA 94305,USA;Department of Otorhinolaryngology-Head and Neck Surgery,Soonchunhyang University Bucheon Hospital,Bucheon 14584,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。